title: Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial.
abstract: Among 103 patients with multidrug-resistant HIV who initiated raltegravir, etravirine, and darunavir/ritonavir-containing regimen in the ANRS 139 TRIO trial, 100 participated in extended follow-up and continued study treatment until week 96. Among them, 87 (87%) received an optimized background therapy including either nucleoside reverse transcriptase inhibitors or enfuvirtide, they were 78 (78%) at week 96. At week 96, 88% achieved durable virologic response (<50 copies/mL). CD4 response was maintained (median change of +150 cells/mm(3)). No major toxicity was reported. This triple drug combination showed sustained efficacy and thus should be strongly considered for patients with multiclass-resistant virus.
authors.affiliation: INSERM, ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, F-33000 Bordeaux, France. catherine.fagard@isped.u-bordeaux2.fr
authors.forename: Catherine
authors.initials: C
authors.lastname: Fagard
authors.forename: Céline
authors.initials: C
authors.lastname: Colin
authors.forename: Charlotte
authors.initials: C
authors.lastname: Charpentier
authors.forename: Agathe
authors.initials: A
authors.lastname: Rami
authors.forename: Christine
authors.initials: C
authors.lastname: Jacomet
authors.forename: Patrick
authors.initials: P
authors.lastname: Yeni
authors.forename: Daniel
authors.initials: D
authors.lastname: Vittecoq
authors.forename: Christine
authors.initials: C
authors.lastname: Katlama
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Molina
authors.forename: Diane
authors.initials: D
authors.lastname: Descamps
authors.forename: Geneviève
authors.initials: G
authors.lastname: Chêne
authors.forename: Yazdan
authors.initials: Y
authors.lastname: Yazdanpanah
mesh_terms: D000328:Adult; D000069454:Darunavir; D024921:Drug Resistance, Multiple, Viral / Q000187:drug effects / Q000235:genetics; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009570:Nitriles; D011724:Pyridazines / Q000008:administration & dosage / Q000009:adverse effects; D011743:Pyrimidines; D011760:Pyrrolidinones / Q000008:administration & dosage / Q000009:adverse effects; D012367:RNA, Viral / Q000032:analysis; D000068898:Raltegravir Potassium; D019438:Ritonavir / Q000008:administration & dosage / Q000009:adverse effects; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D017320:HIV Protease Inhibitors; D009570:Nitriles; D011724:Pyridazines; D011743:Pyrimidines; D011760:Pyrrolidinones; D012367:RNA, Viral; D013449:Sulfonamides; C451734:etravirine; D000068898:Raltegravir Potassium; D019438:Ritonavir; D000069454:Darunavir